BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Irritable Bowel Syndrome readouts · AssetMemo
X-WR-CALDESC:Upcoming phase 1/2 and later readouts in Irritable Bowel Syndr
 ome\, from ClinicalTrials.gov estimates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT07519395-1312@assetmemo.bio
DTSTAMP:20261121T005709Z
DTSTART;VALUE=DATE:20270309
DTEND;VALUE=DATE:20270310
SUMMARY:BLU-5937: Phase 2 readout est. (NCT07519395)
DESCRIPTION:BLU-5937\, phase 2\, Irritable Bowel Syndrome.\nStudy: A Study 
 to Investigate Abdominal Symptoms With Camlipixant Compared With Placebo i
 n Adults With Irritable Bowel Syndrome - Diarrhea (IBS-D) and Irritable Bo
 wel Syndrome - Mixed (IBS-M)\nEstimated primary completion: 9 March 2027. 
 This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and
  it can move.\nDrug page: https://assetmemo.bio/drug/blu-5937#upcoming-eve
 nts\nRegistry record: https://clinicaltrials.gov/study/NCT07519395
URL:https://assetmemo.bio/drug/blu-5937#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05905926-916@assetmemo.bio
DTSTAMP:20261121T005709Z
DTSTART;VALUE=DATE:20310731
DTEND;VALUE=DATE:20310801
SUMMARY:Tenapanor (Ibsrela): Phase 3 readout est. (NCT05905926)
DESCRIPTION:Tenapanor (Ibsrela)\, phase 3\, Irritable Bowel Syndrome with C
 onstipation.\nStudy: Safety Study of Tenapanor for the Treatment of Pediat
 ric Patients (6 to Less Than 18 Years Old) With IBS-C\nEstimated primary c
 ompletion: July 2031. This is a ClinicalTrials.gov estimate\, not a confir
 med readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug
 /tenapanor-ibsrela#upcoming-events\nRegistry record: https://clinicaltrial
 s.gov/study/NCT05905926
URL:https://assetmemo.bio/drug/tenapanor-ibsrela#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
